Stock Research for RIGL

RIGL

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

RIGL Stock Chart & Research Data

The RIGL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RIGL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


RIGL Due diligence Resources & Stock Charts

The RIGL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View RIGL Detailed Price Forecast - CNN Money CNN View RIGL Detailed Summary - Google Finance
Yahoo View RIGL Detailed Summary - Yahoo! Finance Zacks View RIGL Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View RIGL Trends & Analysis - Trade-Ideas Barrons View RIGL Major Holders - Barrons
NASDAQ View RIGL Call Transcripts - NASDAQ Seeking View RIGL Breaking News & Analysis - Seeking Alpha
Spotlight View RIGL Annual Report - CompanySpotlight.com OTC Report View RIGL OTC Short Report - OTCShortReport.com
TradeKing View RIGL Fundamentals - TradeKing Charts View RIGL SEC Filings - Bar Chart
WSJ View Historical Prices for RIGL - The WSJ Morningstar View Performance/Total Return for RIGL - Morningstar
MarketWatch View the Analyst Estimates for RIGL - MarketWatch CNBC View the Earnings History for RIGL - CNBC
StockMarketWatch View the RIGL Earnings - StockMarketWatch MacroAxis View RIGL Buy or Sell Recommendations - MacroAxis
Bullish View the RIGL Bullish Patterns - American Bulls Short Pains View RIGL Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View RIGL Stock Mentions - StockTwits PennyStocks View RIGL Stock Mentions - PennyStockTweets
Twitter View RIGL Stock Mentions - Twitter Invest Hub View RIGL Investment Forum News - Investor Hub
Yahoo View RIGL Stock Mentions - Yahoo! Message Board Seeking Alpha View RIGL Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for RIGL - SECform4.com Insider Cow View Insider Transactions for RIGL - Insider Cow
CNBC View RIGL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for RIGL - OTC Markets
Yahoo View Insider Transactions for RIGL - Yahoo! Finance NASDAQ View Institutional Holdings for RIGL - NASDAQ


Stock Charts

FinViz View RIGL Stock Insight & Charts - FinViz.com StockCharts View RIGL Investment Charts - StockCharts.com
BarChart View RIGL Stock Overview & Charts - BarChart Trading View View RIGL User Generated Charts - Trading View




Latest Financial News for RIGL


Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Posted on Friday April 12, 2024

Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.


Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Posted on Wednesday April 10, 2024

Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 407,325 stock options to nine non-executive employees on April 4, 2024, and 187,500 stock options to Lisa Rojkjaer, Rigel's Chief


Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Posted on Thursday April 04, 2024

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.


Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Posted on Tuesday March 12, 2024

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.